Funder
Japan Agency for Medical Research and Development
Subject
Infectious Diseases,Psychiatry and Mental health,Geriatrics and Gerontology,Public Health, Environmental and Occupational Health,Obstetrics and Gynecology,Health Policy,Pediatrics, Perinatology and Child Health,Internal Medicine
Reference15 articles.
1. RSV infection, IDWR issue No. 22,2004
2. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus;Johnson;J Infect Dis,1997
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group;Pediatrics,1998
4. Safety and pharmacokinetics of palivizumab administered in infants with a history of prematurity or chronic lung disease;Takeuchi;J Jpn Soc Chemother,2002